Error loading player: No playable sources found
VL21CEMAR1/SES105
Revision of EU GMPs Annex 1: What Impacts Can We Expect as an Industry?
Date
March 16, 2021
Explore related products in the following collection:
Revision of EU GMPs Annex 1: What Impacts Can We Expect as an Industry? | 2020 saw the commenting of the draft Annex 1, which included many changes to the 2017 version. In this session, we will cover the commenting process both from the ISPE and the PHSS perspective. Selected topics will be discussed in detail. Based on the outcome of the session with regulators from the 2020 ISPE Annual Meeting, we will give an outlook on the implementation of the final guidance issued by EMA.
Session Leader
Vice President Vetter Development Service External Affairs, Vetter Pharma Fertigung GmbH & Co KG
Speakers
Reg Advisor, ISPE
Head of GMP Compliance, F. Ziel GmbH, Chair, Annex 1 Focus Group, PHSS, Franz Ziel GmbH
Tracks
Related Products
Opening Plenary Session
Opening Plenary Session | In this opening session, representatives from FDA and from industry will give their high-level perspective on where the Pharmaceutical Industry is heading…
Regulatory View on ATMPs and Make vs. Buy
Make vs. Buy in Gene and Cell Therapy and the update on PIC/S Annex 2A Revision for ATMPs will be the topics during this ATMP Session…
Intersection of ATMPs and New Technologies
Intersection of ATMPs and New Technologies | Advanced Therapy Medicinal Products (ATMPs), are medicines for human use that are based on genes, tissues, or cells. ATMPs offer novel ways to treat a variety of diseases, and in some instances can be curative…
Process Safety
Process Safety | Robust and safe processes are the foundation of pharmaceutical manufacturing. Changes to processes are inevitable, but often result in increased risks…
